Table 2.

Treatment related adverse events occurring in ≥10% of patients and possible immune-related adverse events.

Adverse event	Any grade, no. (%)	Grade 1–2, no. (%)	Grade 3, no. (%)	Grade ≥4, no. (%)
	10 (27%)	10 (27%)	0 (0.0)	0 (0.0)
Diarrhea	7 (18.9%)	6 (16.2%)	1 (2.7%)	0 (0.0)
Arthralgia	6 (16.2%)	6 (16.2%)	0 (0.0)	0 (0.0)
Nausea	6 (16.2%)	6 (16.2%)	0 (0.0)	0 (0.0)
Pruritus	6 (16.2%)	6 (16.2%)	0 (0.0)	0 (0.0)
Cough	4 (10.8%)	3 (8.1%)	1 (2.7%)	0 (0.0)
Possible immune-related adverse event
Diarrhea	7 (18.9%)	6 (16.2%)	1 (2.7%)	0 (0.0)
Elevated AST	4 (10.8%)	1 (2.7%)	3 (8.1%)	0 (0.0)
Elevated ALT	4 (10.8%)	3 (8.1%)	1 (2.7%)	0 (0.0)
Elevated Bilirubin	4 (10.8%)	3 (8.1%)	1 (2.7%)	0 (0.0)
Hyperthyroidism	3 (8.1%)	3 (8.1%)	0 (0.0)	0 (0.0)
Colitis	2 (5.4%)	2 (5.4%)	0 (0.0)	0 (0.0)
Skin Rash	2 (5.4%)	2 (5.4%)	0 (0.0)	0 (0.0)
Adrenal Insufficiency	1 (2.7%)	1 (2.7%)	0 (0.0)	0 (0.0)
Hypothyroidism	1 (2.7%)	1 (2.7%)	0 (0.0)	0 (0.0)
Pneumonitis	1 (2.7%)	0 (0.0)	1 (2.7%)	0 (0.0)

AST, aspartate aminotransferase; ALT, alanine aminotransferase.